Medindia LOGIN REGISTER
Medindia
Advertisement

Nexus Pharmaceuticals Receives FDA Approval for Sodium Nitroprusside Injection

Friday, June 2, 2017 Drug News
Advertisement
VERNON HILLS, Ill., June 1, 2017 /PRNewswire/ -- Nexus Pharmaceuticals announced today the immediate availability in the United States of Sodium Nitroprusside Injection. Nexus Pharmaceuticals' Sodium Nitroprusside Injection is available as a single dose vial containing 50 mg per 2mL (25mg/mL) and is an AP Rated generic equivalent of Nitropress®.
Advertisement

Sodium Nitroprusside Injection is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crisis. The product is also indicated for producing controlled hypotension in order to reduce bleeding during surgery and for the treatment of acute congestive heart failure.
Advertisement

About Nexus Pharmaceuticals Inc.

Nexus Pharmaceuticals (www.nexuspharma.net) is a U.S. based healthcare company that specializes in developing and marketing generic sterile injectable products. Through our high quality generic products, Nexus Pharmaceuticals is committed to providing patients with affordable prescription medicines that lower healthcare costs and provide a better quality of life. The company's headquarters is in Vernon Hills, Illinois.

Nitropress® is a registered trademark of Hospira Inc.

Media ContactNexus Pharmaceuticals Inc. Ayesha Ahmed[email protected]

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nexus-pharmaceuticals-receives-fda-approval-for-sodium-nitroprusside-injection-300467416.html

SOURCE Nexus Pharmaceuticals Inc.

Sponsored Post and Backlink Submission


Latest Press Release on Drug News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close